Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
11 févr. 2025 07h45 HE
|
Silo Pharma, Inc.
No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or...
Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment
22 janv. 2025 08h29 HE
|
Silo Pharma, Inc.
SARASOTA, FL, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug...
Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
08 janv. 2025 08h29 HE
|
Silo Pharma, Inc.
SARASOTA, FL, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations...
Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
02 janv. 2025 08h45 HE
|
Silo Pharma, Inc.
IND submission for intranasal SPC-15 treatment expected in 2025; Phase 1 clinical trial to follow upon approvalSP-26 ketamine implants nearing first animal studies SARASOTA, FL, Jan. 02, 2025 ...
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
18 déc. 2024 07h35 HE
|
Silo Pharma, Inc.
Key preclinical milestone for novel, non-opioid extended-release pain therapeutic SARASOTA, FL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a...
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
29 nov. 2024 08h05 HE
|
Silo Pharma, Inc.
Prototype development and feasibility testing underway for optimized subcutaneous delivery SARASOTA, FL, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the...
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
18 nov. 2024 08h40 HE
|
Silo Pharma, Inc.
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions The Company is currently developing...
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
31 oct. 2024 08h35 HE
|
Silo Pharma, Inc.
The implant demonstrates stability and consistent drug release, supporting further analytical testing and development SARASOTA, FL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
10 sept. 2024 06h35 HE
|
Silo Pharma, Inc.
Proposal submitted for FDA 505(b)(2) regulatory pathway for SPC-15 approval Advancing path to IND submission for first-in-human trials SARASOTA, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ...
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
14 août 2024 14h30 HE
|
Silo Pharma, Inc.
SP-26 dissolvable ketamine-based injectable implant targets chronic pain and fibromyalgia Sever Pharma to scale-up extrusion processes and continue analytical testing for novel non-opioid treatment ...